Article Text

Download PDFPDF
MAFLD, HCC and the dilemma of (changing) terminology in liver diseases
  1. Ruben Hernaez1,2,
  2. Markus Peck-Radosavljevic3
  1. 1Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA
  2. 2Gastroenterology and Hepatology, Michael E DeBakey VA Medical Center, Houston, Texas, USA
  3. 3Innere Medizin und Gastroenterologie (IMuG), Klinikum Klagenfurt am Worthersee, Klagenfurt, Austria
  1. Correspondence to Professor Markus Peck-Radosavljevic, Innere Medizin und Gastroenterologie (IMuG), Klinikum Klagenfurt am Worthersee, 9020 Klagenfurt, Austria; markus{at}peck.at

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The exclusion of alcohol to diagnose non-alcoholic fatty liver disease (NAFLD) has long been a semantical and technical nuisance. The accurate assessment of long-term alcohol use is complex and prone to error. Further, the relatively low cut-offs for alcohol as the predominant aetiological factor seem overly strict, precluding a NAFLD diagnosis in patients with relevant metabolic factors and moderate alcohol consumption. A group of experts proposed the term metabolic associated fatty liver disease (MAFLD) to ‘reflect the metabolic (dys)function-associated fatty liver disease’ and provide a more overarching, inclusive term,1 in contrast to the ‘exclusion’-based term NAFLD. Patients with MAFLD with other contributing factors should be defined as having dual (or more) aetiology fatty liver disease.2

Vitale et al used this newly coined term MAFLD to reanalyse patients with hepatocellular carcinoma (HCC) retrospectively, using the well-established Italian Liver Cancer (ITA.LI.CA) group.3 The authors analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 in 23 Italian Liver Cancer centres, with at least 2-year follow-up. They grouped the patients using the novel MAFLD concept in three categories: single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD) and non-MAFLD. The majority of patients with HCC had MAFLD (68.4%). The proportion of S-MAFLD significantly increased over the study period from 3.6% (2002–2003) to 28.9% (2018–2019). In contrast, M-MAFLD remained constant (46.8% in the first biennium to 48.4% in the last period); and non-MAFLD, decreased from 49.6% to 22.7%. The findings regarding the outcomes, in particular survival, are interesting but not conclusive. When the authors grouped patients according to the MAFLD definition, they found a lower median overall survival in non-MAFLD (23.8 months) than S-MAFLD (28.1 months) and M-MAFLD (27.1 months). While HCC-related and liver …

View Full Text

Footnotes

  • Twitter @MarkusPeck1

  • Contributors MP-R and RH both wrote the manuscript together; this is an invited Editorial.

  • Funding The work is supported in part by the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413), Michael E DeBakey VA Medical Center, Houston, Texas, USA.

  • Disclaimer The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Hepatology
    Alessandro Vitale Gianluca Svegliati-Baroni Alessio Ortolani Monica Cucco Giulio V Dalla Riva Edoardo G Giannini Fabio Piscaglia Gianludovico Rapaccini Mariella Di Marco Eugenio Caturelli Marco Zoli Rodolfo Sacco Giuseppe Cabibbo Fabio Marra Andrea Mega Filomena Morisco Antonio Gasbarrini Francesco Giuseppe Foschi Gabriele Missale Alberto Masotto Gerardo Nardone Giovanni Raimondo Francesco Azzaroli Gianpaolo Vidili Filippo Oliveri Filippo Pelizzaro Rafael Ramirez Morales Umberto Cillo Franco Trevisani Luca Miele Giulio Marchesini Fabio Farinati for the Italian Liver Cancer (ITA.LI.CA) group Anna Sartori Angela Imondi Barbara Penzo Maurizio Biselli Paolo Caraceni Francesca Garuti Annagiulia Gramenzi Andrea Neri Davide Ramboldi Valentina Santi Alessandro Granito Luca Muratori Fabio Piscaglia Vito Sansone Francesco Tovoli Elton Dajti Giovanni Marasco Federico Ravaioli Alberta Cappelli Rita Golfieri Cristina Mosconi Matteo Renzulli Ester Marina Cela Antonio Facciorusso Valentina Cacciato Edoardo Casagrande Alessandro Moscatelli Gaia Pellegatta Nicoletta de Matthaeis Gloria Allegrini Valentina Lauria Giorgia Ghittoni Giorgio Pelecca Fabrizio Chegai Fabio Coratella Mariano Ortenzi Elisabetta Biasini Andrea Olivani Alessandro Inno Fabiana Marchetti Anita Busacca Giuseppe Cabibbo Calogero Cammà Vincenzo Di Martino Giacomo Emanuele Maria Rizzo Maria Stella Franzè Carlo Saitta Assunta Sauchella Vittoria Bevilacqua Dante Berardinelli Alberto Borghi Andrea Casadei Gardini Fabio Conti Alessandro Cucchetti Anna Chiara Dall’Aglio Giorgio Ercolani Claudia Campani Chiara Di Bonaventura Stefano Gitto Pietro Coccoli Antonio Malerba Mario Capasso Maria Guarino Filippo Oliveri Veronica Romagnoli Alessandro Di Bucchianico